Background
Pathophysiology of spondyloarthropathies
Biologic agents in JSpA
Experience in pediatric cohorts
Anti-TNF agents
Source | Drug | JSpA patients (n) | Study duration | Outcomea
| Study design |
---|---|---|---|---|---|
Henrickson [37] | ETNERCEPT | 8 | 24 months | improvementb
| Open-label Uncontrolled |
Tse [38] | ETANERCEPT | 2 | |||
INFLIXIMAB | 8 | 12 months | improvement | Open-label Uncontrolled | |
Sulpice [39] | 20 (23 treatments) | ||||
ETANERCEPT | 19 | 12 months | improvement | Retrospective Cohort | |
INFLIXIMAB | 3 | ||||
ADALIMUMAB | 1 | ||||
Otten [40] | 22 (24 treatments) | ||||
ETANERCEPT | 20 | ||||
INFLIXIMAB | 2 | 24 months | improvement | Multicenter Observational Register | |
ADALIMUMAB | 2 | ||||
Horneff [41] | ADALIMUMAB | 17 | 6 months | improvement | Double-Blind Placebo-controlled |
Horneff [42] | ETANERCEPT | 122 | 3 months | improvement | Open-label |
Uncontrolled | |||||
Burgos Vargas [43] | ADALIMUMAB | 46 | 12 months | improvement | Double-Blind Placebo-controlled |
Hugle B [44] | INFLIXIMAB | 10 | 84 months | Open-label | |
ETANERCEPT | 6 | improvement | Observational | ||
Horneff G [45] | ETANERCEPT | 41 | 12 months | improvement | Double-Blind Placebo- controlled |